Diabetes mellitus: An opportunity for therapy with stem cells?

Regenerative Medicine

Volumn 3, Issue 3, 2008, Pages 377-397

  Sordi, Valeria ^a   Bertuzzi, Federico ^b   Piemonti, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

cell proliferation; Cell therapy; Diabetes; Stem cell

Indexed keywords

BOMBESIN; CHOLECYSTOKININ; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTRIN; GASTROINTESTINAL HORMONE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; METFORMIN; ROSIGLITAZONE; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR PDX 1; TROGLITAZONE; INSULIN;

AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL REGENERATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG MECHANISM; EPITHELIUM CELL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL; MESENCHYME CELL; MONOTHERAPY; NEURAL STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOLYSIS; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SIDE EFFECT; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DISEASE MODEL; GLUCOSE BLOOD LEVEL; METABOLISM; METHODOLOGY; MOUSE; PANCREAS ISLET BETA CELL; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CELL DIFFERENTIATION; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; MODELS, BIOLOGICAL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TREATMENT OUTCOME;

EID: 48849088546     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.3.377     Document Type: Review

References (246)

1. Wild S, Roglic C, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
2. Faber OK, Binder C: C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. Diabetes 26(7), 605-610 (1977).
3. Keymeuleri B, Vandemeulebroucke E, Ziegler AG et al.: Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J Med. 352(25), 2598-2608 (2005).
4. Butler AE, Janson J, Bonner-Weir S et al.: β-cell deficit and Increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes 52(1), 102-110 (2003).
5. Hu FB, Stampfer MJ, Solomon CG et al.: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arrh. Intern. Med. 161(14), 1717-1723 (2001).
6. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W: Associations of diabetes meNitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch, Intern. Med. 167(l)), 1145-1151 (2007).
7. Clarke WL, Kovatchev B: The artificial pancreas: how close are we to closing the loop? Peoiatir. Endocrinol. Rev. 4(4), 314-316 (2007).
8. Shapiro AM, Ricordi C, Hering BJ et al.: International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355 (13), 1318-1330 (2006).
9. Butler PC, Meier JJ, Butler AE, Bhushan A: The replication of β cells in normal physiology, in disease and for therapy. Nat. Clin. Pract. Endocrinol Metab. 3 (11). 758-768 (2007).
10. Lipsett M, Aikin R, Hanley S et al.: Islet neogenesis: a potential therapeutic tool in Type 1 diabetes. Int. J Biochem. Cell Biol. 38(5-6), 715-720 (2006).
11. Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B: β-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 49(8), 1325-1333 (2000).
12. Bock T, Kyhnel A, Pakkenberg B, Buschard K: The postnatal growth of the β-cell mass in pigs. J. Endocrinol. 179(2), 245-252 (2003).
13. Montanya E, Nacher V, Biarnes M, Soler J: Linear correlation oetween β-cell mass and body weight throughout the lifespan in Lewis rats: role of β-cell hyperplasia and hypertrophy. Diabetes 49(8), 1341-1346 (2000).
14. Kioppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of Type 1 and Type 2 diabetes mellitus revisited. Surv Synth. Pathol. Res. 4(2), 110-125 (1985).
15. Pick A, Clark J, Kubstrup C et al.: Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47(3), 358-364 (1998).
16. Bock T, Pakkenberg B, Buschard K: Increased Islet volume but unchanged islet number in ob/ob mice. Diabetes 52(7), 1716-1722 (2003).
17. Tomita T, Douli V, Pollock HG, Krizsan D: Pancreatic islets of obese hyperglycemic mice (ob/ob). Pancreas 7 (3), 367-375 (1992).
18. Wang Q, Brubaker PL: Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45(9), 1263-1273 (2002).
19. Gapp DA, Leiter EH, Coleman DL, Schwizer RW: Temporal changes in pancreatic islet composition in C57BL/6J-db/db (diabetes) mice. Diabetologia 25(5), 439-443 (1953).
20. Van Assehe FA, Aerts L, De Prins F: A morphological study of the endocrine pancreas in human pregnancy. Br. J. Obstet. Gynaerol. 85(11), 818-820 (1978).
21. Blondeau B, Garofano A, Czernichow P, Breant B: Age-dependent inability of the endocrine pancreas to adapt to pregnancy: a long-term consequence of perinatal malnutrition in the rat. Endocrinology 140(9), 4208-4213 (1999).
22. Scaglia L, Smith FE, Bonner-Weir S: Apoptosis contributes to the involution of β-cell mass in the post partum rat pancreas. Endocrinology 136(12), 5461-5468 (1995).
23. Marynissen G, Aerts L, Van Assche FA: The endocrine pancreas during pregnancy and lactation in the rat. J. Dev. Pbysiol. 5(6), 373-381 (1983).
24. Blume N, Skouv J, Larsson LI, Hoist JJ, Madsen OD: Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. J. Clin. Invest. 96(5), 2227-2235 (1995).
25. Finegood DT, Scaglia L, Bonner-Weir S: Dynamics of β-cell mass in the growing rat pancreas. Estimation with a simple mamematical model. Diabetes 44(5), 249-256 (1995).
26. Dhawan S, Georgia S, Bhushan A: Formation and regeneration of the endocrine pancreas. Curr. Opin. Cell Biol. 19(6), 634-645 (2007).
27. Dor Y, Brown J, Martinez OI, Melton DA: Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429(6987), 41-46 (2004).
28. Nir T, Melton DA, Dor Y: Recovery from diabetes in mice by β cell regeneration. J. Clin. Invest. 117(9), 2553-2561 (2007).
29. Dor Y: β-cell proliferation is the major source of new pancreatic β cells. Nat. Clin. Pract. Endocrinol. Metab. 2(5), 242-243 (2006).
30. Teta M, Rankin MM, Long SY, Stein GM, Kushner JA: Growth and regeneration of adult β cells does not involve specialized progenitors. Dev. Cell 12(5), 817-826 (2007).
31. Uchida T, Nakamura T, Hashimoto N et al.: Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat. Med. 11(2), 175-182 (2005).
32. Georgia, S, Bhushan A: β cell replication is the primary mechanism for maintaining postnatal β cell mass. J. Clin. Invest. 114(7), 963-968 (2004).
33. Kushner JA, Ciemerych MA, Sicinska E et al.: Cyclins D2 and D1 are essential for postnatal pancreatic β-cell growth. Mol. Cell Biol. 25(9), 3752-3762 (2005).
34. Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA et al.: Molecular control of cell cycle progression in the pancreatic β-cell. Endocr. Rev. 27(4), 356-370 (2006).
35. Fatrai S, Elghazi L, Balcazar N et al.: Akt induces β-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes 55(2), 318-325 (2006).
36. Fajas L, Annicotte JS, Miard S et al.: Impaired pancreatic growth, β cell mass, and β cell function in E2F1 (-/-) mice. J. Clin. invest. 115(9), 1288-1295 (2004).
37. Iglesias A, Murga M, Laresgoiti U et al.: Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double-mutant mice. J. Clin. Invest. 113(10), 1398-1407 (2004).
38. Li FX, Zhu JW, Tessem JS et al.: The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells In preventing islet cell loss. Proc. Natl Acad. Sci. USA 100(22), 12935-12940 (2003).
39. Rane SG, Dubus P, Mettus RV et al.: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat. Genet. 22(1), 44-52 (1999).
40. Cozar-Castellano I, Weinstock M, Haught M et al.: Evaluation of β-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. Diabetes 55(1), 70-77 (2006).
41. Vasavada RC, Cozar-Castellano I, Sipula D, Stewart AF: Tissue-specific deletion of the retinoblastoma protein in the pancreatic β-cell has limited effects on β-cell replication, mass, and function. Diabetes 56(1), 57-64 (2007).
42. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell Biol 20(16), 6147-6158 (2000).
43. Karnik SK, Hughes CM, Gu X et al.: Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p181NK4c. Proc. Natl Acad. Sci. USA 102(41), 14659-14664 (2005).
44. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA: Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 55(5), 1146-1151 (1995).
45. Williams BO, Remington L, Albert DM et al.: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet. 7(4), 480-484 (1994).
46. Butler AE, Janson J, Soeller WC, Butler PC: Increased β-cell apoptosis, prevents adaptive increase in β-cell mass in mouse model of Type 2 diabetes: evidence for role of islet amylold formation rather than direct action of amyloid. Diabetes 52 (9), 2304-2314 (2003).
47. Bonner-Weir S, Trent DF, Weir GC: Partial pancreatectomy in ine rat ano subsequent defect in glucose-induced insulin release. J. Clin. Invest. 71(6), 1544-1553 (1983).
48. De Leon DD, Deng S, Madani R et al.: Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52(2), 365-371 (2003).
49. Plachot C, Movassat J, Portha B: Impaired β-cell regeneration after partial pancreatectomy in the adult Goto-Kakizaki rat, a spontaneous model of Type II diabetes. Histochem. Cell Biol. 116(2), 131-139 (2001).
50. Robertson RP, Lanz KJ, Sutherland DE, Seaquist ER: Relationship between diabetes and obesity 9 to 18 years after hemipancreatectomy and transplantation in donors and recipients. Transplantation 73(5), 736-741 (2002).
51. Matveyenko AV, Veldhuis JD, Butler PC: Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 55(8), 2347-2356 (2006).
52. Stagner JI, Samols E: Deterioration of islet β-cell function after hemipancreatectomy in dogs. Diabetes 40(11), 1472-1479 (1991).
53. Ritzel RA, Butler PC: Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52(7), 1701-1708 (2003).
54. Beattie GM, Montgomery AM, Lopez AD et al.: A novel approach to increase human islet cell mass while preserving β-cell function. Diabetes 51(12), 3435-3439 (2002).
55. Suarez-Pinzon WL, Yan Y, Power R, Brand SJ, Rabinovitch A: Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54(9), 2596-2601 (2005).
56. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC: Increased islet β cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 49 (11), 2689-2696 (2006).
57. Parnaud G, Bosco D, Berney T et al.: Proliferation of sorted human and rat β cells. Diabetologia 51(1), 91-100 (2008).
58. Brun T, He KH, Lupi R et al.: The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1. Hum. Mol. Genet. 17(4), 478-489 (2008).
59. Marchetti P, S. Del Guerra, Marselli L et al.: Pancreatic islets from Type 2 diabetic patients have functional defects and increased apoptosis that am ameliorated by mettormun. J. Clin. Endocrinol. Metab. 89(11), 5535-5541 (2004).
60. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications In overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352(9131), 854-865 (1998).
61. Kahn SE, Haffner SM, Heise MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427-2443 (2006).
62. Buchanan TA, Xiang AH, Peters RK et al.: Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51(9), 2796-2803 (2002).
63. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC: Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J. Clin. Endocrinol. Metab. 90(12), 6678-6686 (2005).
64. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarcition and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
65. Lupi R, Del Guerra S, Bugliani M et al.: The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur. J. Endocrinol. 154(2), 355-361 (2006).
66. Bosch J, Yusuf S, Gerstein HC et al.: Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355(15), 1551-1562 (2006).
67. Maedier K, Carr RD, Bosco D et al.: Sulfonylurea induced β-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90(1), 501-506 (2005).
68. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC: UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. 15(4), 297-303 (1998).
69. Narushirna M, Kobayashi N, Okitsu T et al.: A human β-cell line for transplantation therapy to control Type 1 diabetes. Nat. Bioeachnol. 23(10), 1274-1282 (2005).
70. + cells are islet progenitors and are distinct from duct progenitors. Development 129(10), 2447-2457 (2002).
71. Murtaugh LC, Melton DA: Genes, signals, and lineages in pancreas development. Annu. Rev. Cell Dev. Biol. 19, 71-89 (2003).
72. Vionnet N, Stoffel M, Takeda J et al.: Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 356 (6371), 721-722 (1992).
73. Stoffers DA, Ferrer J, Clarke WL, Habener JF: Early-onset Type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. 17(2), 138-139 (1997).
74. Horikawa Y, Iwasaki N, Hara M et al.: Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nat. Genet. 17(4), 384-385 (1997).
75. Yamagata K, Furuta H, Oda N et al.: Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 384(6608), 458-460 (1996).
76. Yamagata K, Oda N, Kaisaki PJ et al.: Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 384(6608), 455-458 (1996).
77. Malecki MT, Jhala US, Antonellis A et al.: Mutations in NEUROD1 are associated with the development of Type 2 diabetes mellitus. Nat. Genet. 23(3), 323-328 (1999).
78. Gittes CK, Galante PE, Hanahan D, Rutter WJ, Debase HT: Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors. Development 122(2), 439-447 (1996).
79. Seaberg RM, Smukler SR, Kieffer TJ et al.: Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat. Biotechnol. 22(9), 1115-1124 (2004).
80. Suzuki A, Nakauchi H, Taniguchi H: Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 53(8), 2143-2152 (2004).
81. Hao E, Tyrberg B, Itkin-Ansari P et al.: β-cell differentiation from nonendocrine epithelial cells of the adult human pancreas. Nat. Med. 12(3), 310-316 (2006).
82. Ramiya VK, Maraist M, Arfors KE et al.: Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat. Med. 6(3), 278-282 (2000).
83. Bonner-Weir S, Taneja M, Weir GC et al.: In vitro cultivation of human islets from expanded ductal tissue. Proc. Natl Acad. Sci. USA 97(14), 7999-8004 (2000).
84. Yatoh S, Dodge R, Akashi T et al.: Differentiation of affinity-purified human pancreatic duct cells to β-cells. Diabetes 56(7), 1802-1809 (2007).
85. Kim BM, Kim SY, Lee S et al.: Clusterin induces differentiation of pancreatic duct cells into insulin-secreting cells. Diabetologia 49(2), 311-320 (2006).
86. Heremans Y, Van De Casteele M, in't Veld P et al.: Recapitulation of embryonic neuroendocrine differentiation in adult human pancreatic duct cells expressing neurogenin 3. J. Cell Biol. 159(2), 303-312 (2002).
87. Inada A, Nienaber C, Fonseca S, Bonner-Weir S: Timing and expression pattern of carbonic anhydrase II in pancreas. Dev. Dyn. 235(6), 1571-1577 (2006).
88. Xu X, D'Hoker J, Stange G et al.: β cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132(2), 197-207 (2008).
89. Lardon J, Huyens N, Rooman I, Bouwens L: Exocrine cell transdifferentiation in dexamethasone-treated rat pancreas. Virchows Arch. 444(1), 61-65 (2004).
90. Baeyens L, De Breuck S, Lardon J et al.: In vitro generation of insulin-producing β cells from adult exocrine pancreatic cells. Diabetologia 48(1), 49-57 (2005).
91. Minami K, Okuno M, Miyawaki K et al.: Lineage tracing and characterization of insulin-secreting cells generated from adult pancreatic acinar cells. Proc. Natl Acad. Sci. USA 102(42), 15116-15121 (2005).
92. Desai BM, Oliver-Krashiski J, De Leon DD et al.: Preexisting pancreatic acinar cells contribute to acinar cell, but not islet β cell regeneration. J. Clin. Invest., 117(4), 971-977 (2007).
93. Zulewski H, Abraham EJ, Gerlach MJ et al.: Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50(3), 521-533 (2001).
94. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF: Insulinotropic hormone glucagob-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143(8), 3152-3161 (2002).
95. Maria-Engler SS, Correa-Gianneila ML, Labriola L et al.: Co-localization of nestin and insulin and expression of islet cell markers in long-term human pancreatic nestin-positive cell cultures. J. Endocrinol. 183(3), 455-467 (2004).
96. Huang H, Tang X: Phenotypic determination and characterization of nestin-positive precursors derived from human fetal pancreas. Lab. Invest. 83(4), 539-547 (2003).
97. Bernardo AS, Barrow J, Hay CW et al.: Presence of endocrine and exocrine markers in EGFP-positive cells from the developing pancreas of a nestin/EGFP mouse. Mol. Cell Endocrinol. 253(1-2), 14-21 (2006).
98. Wang R, Li J, Yashpal N, Gao N: Nestin expression and clonal analysis of islet-derived epithelial monolayers: insight into nestin-expressing cell heterogeneity and differentiation potential. J. Endocrinol. 184(2), 329-339 (2005).
99. Eberhardt M, Salmon P, von Mach MA et al.: Multipotential nestin and Isl-1 positive mesenchymal stem cells isolated from human pancreatic islets. Biochem. Biophys Res. Commun. 345(3), 1167-1176 (2006).
100. Piper K, Ball SG, Turnpenny LW et al.: β-cell differentiation during human development does not rely on nestin-positive precursors: implications for stem cell-derived replacemed-therapy. Diabetologia 45(7), 1045-1047 (2002).
101. Lardon J, Roopman J, Bouwens L.: Nestin expression in pancreatic stellate cells and angiogenic: endothelial cells. Histochem. Cell Biol. 117(6), 535-540 (2002).
102. Klein T, Ling Z, Heimberg H et al.: Nestin is expressed in vascular endothelial cells in the adult human pancreas. J. Histochem. Cytochem. 51(6), 697-706 (2003).
103. Treutelaar MK, Skidmore JM, Dias-Leme CL et al.: Nestin-lineage cells contribute to the microvasculature but not endocrine cells of the islet. Diabetes 52(10), 2503-2512 (2003).
104. Esni F, Stoffers DA, Takeuchi T, Leach SD: Origin of exocrine pancreatic cells from nestin-positive precursors in developing mouse pancreas. Mech. Dev. 121(1), 15-25 (2004).
105. Delacour A, Nepote V, Trumpp A, Herrera PL: Nestin expression in pancreatic exocrine cell lineages. Mech. Dev. 121(1), 3-14 (2004).
106. Humphrey RK, Bucay N, Beattle GM et al.: Characterization and isolation of promoter-defined nestin-positive cells from the human fetal pancreas. Diabetes 52(10), 2519-2525 (2003).
107. Gershengorn MC, Geras-Raaka E, Hardikar AA, Raaka BM: Are better islet cell precursors generated by epithelial-to-mesenchymal transition? Cell Cycle 4(3), 380-382 (2005).
108. Ouziel-Yahalom L, Zalzman M, Anker-Kitai L et al.: Expansion and redifferentiation of adult human pancreas islet cells. Biochem. Biophys. Res. Commun. 341(2), 291-298 (2006).
109. Lechner A, Nolan AL, Blacken RA, Habener JF: Redifferentiation of insulin-secreting cells after in vitro expansion of adult human pancreatic islet tissue. Biochem. Biophys. Res. Commun. 327(2), 581-588 (2005).
110. Gershengorn MC, Hardikar AA, Wei C et al.: Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306 (5705), 2261-2264 (2004).
111. Seeberger KL, Dufour JM, Shapiro AM et al.; Expansion of mesenchymal stem cells from human pancreatic ductal epithelium. Lab Invest. 86(2), 141-153 (2006)
112. Linning KD, Tai MH, Madhukar BV ety al.: Redox-mediated enrichment of self-renewing adult human pancreatic cells that possess endocrine differentiation potential. Pancreas 29(3), E64-E76 (2004).
113. Sordi V, Malosio ML, Marchesi F et al.: Done marrow mesenchymal stem cells express a restricted set of functionally active Chemokine receptors capable of promoting migration to pancreatic islets. Blood 106(2), 419-427 (2005).
114. Davani B, Ikonomou L, Raaka BM et al.: Human islet-derived precursor cells am mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 25 (12). 3215-3222 (2007).
115. Atouf F, Park CH, Pechhold K et al.: No evidence for mouse pancreatic β-cell epithelial-mesenchymal transition in vitro. Diabetes 56 (3), 699-702 (2007).
116. Weinberg N, Ouziel-Yahalom L, Knoller S, Efrat S, Dor Y. Lineage tracing evidence for in-vitro dedifferentiation, but rare proliferation, of mouse pancreatic {β} cells. Diabetes (2007).
117. Morton RA, Geras-Raaka E, Wilson LM, Raaka BM, Gershengorn MC: Endocrine precursor cells from mouse islets are not generated by epithelial-to-mesenchymal transition of mature β cells. Mol. Cell Endocrinol. 270(1-2), 87-93 (2007).
118. Chase LG, Ulloa-Montoya F, Kidder BL, Verfaillie CM: Islet-derived fibroblast-like cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells. Diabetes 56(1), 3-7 (2007).
119. Grapin-Botton A, Melton DA: Endoderm development: from patterning to organagenesis: Trends Genet 16(3), 124-130 (2000).
120. Deutsh G, Jung J, Zheng M, Lora J, Zaret KS: A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 128 (6), 871-81 (2001).
121. Tosh D, Slack JM: How cells change their phenotype. Nat. Rev. Mol. Cell Biol. 3(3), 187-194 (2002).
122. Tosh D, Shen CN, Slack JM: Conversion of pancreatic cells to nepatocytes. Biochem. Soc. Trans. 30(2), 51-55 (2002).
123. Grompe M: Pancreatic-hepatic switches in vivo. Mech. Dev. 120(1), 92-106 (2003).
124. Fujita Y, Cheung AT, Kieffer TJ: Harnessing the gut to treat diabetes. Pediatr. Diabetes 5(Suppl. 2), 57-69 (2004).
125. Ferber S, Halkin A, Cohen H et al.: Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat. Med. 6(5), 568-572 (2000).
126. Zalzman M, Gupta S, Giri RK et al.: Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc. Natl Acad. Sci. USA 100(12), 7253-7258 (2003).
127. Shen CN, Horb ME, Slack JM, Tosh D: Transdifferentiation of pancreas to liver. Mech. Dev. 120(1), 107-116 (2003).
128. Kojima H, Fujimiya M, Matsumura K et al.: NeuroD-βcellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat. Med. 9(5), 596-603 (2003).
129. Miyatsuka T, Kaneto H, Kajimoto Y et al.: Ectopically expressed PDX-1 in liver initiates endocrine and exocrine pancreas differentiation but causes dysmorphogenesis. Biochem. Biophys. Res. Commun. 310(3), 1017-1025 (2003).
130. Imai J, Katagiri H, Yamada T et al.: Constitutively active PDX1 induced efficient insulin production in adult murine liver. Biochem. Biophys. Res. Commun. 326(2), 402-409 (2005).
131. Cao LZ, Tang DQ, Horb ME, Li SW, Yang Q: High glucose is necessary for complete maturation of Pdx1-VP16-expressing hepatic cells into functional insulin-producing cells. Diabetes 53(12), 3168-3178 (2004).
132. Sapir T, Shternhall K, I. Meivar-Levy et al.: Cell-replacernent therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells. Proc. Natl Acad. Sci. USA 102(22), 7964-799 (2005).
133. Zalzman M, L. Anker-Kitai, Efrat S: Differentiation of human liver-derived, insulin-producing cells toward the β-cell phenotype. Diabetes 54 (9), 2568-2575 (2005).
134. Yang L. Li S, Hatch H et al.: In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc. Natl Acad. Sci. USA 99(12), 8078-8083 (2002).
135. Cheung AT, Dayanandan B, Lewis JT et al.: Glucose-dependent insulin release from genetically engineered K cells. Science 290(5498), 1959-1962 (2000).
136. Jiang Y, Jahagirdar BN, Reinhardt RL et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49 (2002).
137. Tang DQ, Cao LZ, Burkhardt BR et al.: In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 53(7), 1721-1732 (2004).
138. Chen LB, Jiang XB, Yang L: Differentiation of rat marrow mesenchymal stem cells into pancreatic islet β-cells. World J. Gastroenterol. 10(20), 3016-3020 (2004).
139. Oh SH, Muzonigro TM, Bae SH et al.: Adult bone marrow-derived cells transdifferentiating into insulin-producing cells for the treatment of Type I diabetes. Lab. Invest. 84(5), 607-617 (2004).
140. Moriscot C, de Fraipont F, Richard MJ et al.: Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells 23(4), 594-603 (2005).
141. Timper K, Seboek D, Eberhardt M et al.: Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem. Biophys. Res. Commun. 341(4), 1135-1140 (2006).
142. Zhao Y, Glesne D, Huberman E: A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc. Natl Acad. Sci. USA 100(5), 2426-2431 (2003).
143. Ruhnke M, Ungefroren H, Nussler A et al.: Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology 128(7), 1774-1786 (2005).
144. Ianus A, Holz GG, Theise ND, Hussain MA, In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J. Clin. Invest. 111(6), 843-850 (2003).
145. Lechner A, Yang YG, Blacken RA et al.: No evidence for significant transdifferentiation of bone marrow into pancreatic β-cells in vivo. Diabetes 53(3), 616-623 (2004).
146. Choi JB, Uchino H, Azuma K et al.: Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic β-cells. Diabetologia 46(10), 1366-1374 (2003).
147. Taneera J, Rosengren A, Renstrom E et al.: Failure of transplanted bone marrow cells to adopt a pancreatic β-cell fate. Diabetes 55(2), 290-296 (2006).
148. Wang X, Willenbring H, Akkari Y et al.: Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422(6934), 897-901 (2003).
149. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL: Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297 (5590). 2256-2259 (2002).
150. Butler AE, Huang A, Rao PN et al.: Hematopoietic stem cells derived from adult donors are not a source of pancreatic β-cells in adult nondiabetic humans. Diabetes 56(7), 1810-1816 (2007).
151. Luo L, Badiavas E, Luo JZ, Maizel A: Allogeneic bone marrow supports human islet β cell survival and function over six mounths. Biochem. Biophys. Res. Commun. 361(4), 859-864 (2007).
152. Hasegawa Y, Ogthara T, Yamada T et al.: Bone marrow (BM) transplantation promotes β-cell regeneration after acute injury through BM cell mobilization. Endocrinology 148(5), 2006-2015 (2007).
153. Mathews V, Hanson PT, Ford E et al.: Recruitment of bone marrow-derived endothelial cells to sites of pancreatic β-cell injury. Diabetes 53(1), 91-98 (2004).
154. Banerjee M, Kumar A, Bhonde RR: Reversal of experimental diabetes by multiple bone marrow transplantation. Biochem. Biophys. Res. Commun. 328(1), 318-325 (2005).
155. Izumida Y, Aoki T, Yasuda D et al.: Hepatocyte growth factor is constitutively produced by donor-derived bone marrow cells and promotes regeneration of pancreatic β-cells. Biochem. Biophys. Res. Commun. 333(1), 273-282 (2005).
156. Lee RH, Seo MJ, Reger RL et al.: Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl Acad. Sci. USA 103(46), 17438-1743 (2006).
157. Hutson EL, Boyer S, Genever PG: Rapid isolation, expansion, and differentiation of osteoprogenitors from full-term umbilical cord blood. Tissue Eng. 11(9-10), 1407-1420 (2005).
158. Zhao Y, Wang H, Mazzone T: Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp. Cell Res. 312(13), 2454-2464 (2006).
159. Pessina A, Eletti B, Croera C et al.: Pancreas developing markers expressed on human morionucleated umbilical cord blood cells. Biochem. Biophys. Res. Commun. 323(1), 315-322 (2004).
160. Yoshida S, Ishikawa F, Kawano N et al.: Human cord blood-derived cells generate insulin-producing cells in vivo. Stem Cells 23(9), 1409-1416 (2005).
161. Denner L, Bodenburg Y, Zhao JG et al.: Directed engineering of umbilical cord blood stem cells to produce C-pepticle and insulin. Cell Prolif 40(3), 367-380 (2007).
162. Sun B, Roh KH, Lee SR, Lee YS, Kang KS: Induction of human umbilical cord blood-derived stem cells with embryonic stem cell phenotypes into insulin producing islet-like structure. Biochem. Biophys. Res. Commun. 354(4), 919-923 (2007).
163. Ende N, Chen R, Reckli AS: Transplantation at human umbilical cord blood cells improves glycemia and glomerular hypertrophy in Type 2 diabetic mice. Biochem. Biophys. Res. Commun. 321(1), 168-171 (2004).
164. Ende N, Chen R, Reddi AS: Effect of human umbilical cord blood cells on glycemia and insulitis in Type 1 diabetic mice. Biochem. Biophys. Res. Commun. 325(3), 665-669 (2004).
165. Voltareli JC, Court CE, Stracieri AB et al.: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 297 (14), 1568-1576 (2007).
166. Haller M, Viener H, Brusko T et al.: Insulin requirements, HbA1c, stimulated C-peptide following autologous umbilical cord Blood transfusion in children with T1D. Presented at: Annual Meeting of the American Diabetes Awaration Scientific Sessions. Chicago, IL, USA, 2-26 June 2007.
167. Fernandez-Viñan RJ, Andrin O, Saslavsky J et al.: First reported data from Argentina of implant and cellular therapy in patients with diabetes Type 2 (TECELDIAB Study). Presented at: 45th Annual Meeting of the American Society of Cell Biology. San Francisco, CA, USA 10-14 December 2005.
168. Hori Y, Gu X, Xie X, Kim SK: Differentiation of insulin-producing cells from human neural progenitor cells. PLoS Med. 2(4), E103 (2005).
169. Shi CM, Cheng TM: Differentiation of dermis-derived multipotent cells into insulin-producing pancreatic cells in vitro. World J. Gastroenterol. 10(17), 2550-2552 (2004).
170. Hisatomi Y, Okumura K, Nakamura K et al.: Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. Hepatology 39(3), 667-675 (2004).
171. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL: Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302(5648), 1223-1227 (2003).
172. Chong AS, Snen J, Tao J et al.: Reversal at diabetes in non-obese diabetic mice without spleen cell-clerived β cell regeneration. Science 311(5768), 1774-1775 (2006).
173. Nishio J, Gaglia JL, Turvey SE et al.: Islet recovery and reversal of murine Type 1 diabetes in the absence of any infused spleen cell contribution. Science 311(5768), 1775-1778 (2006).
174. Suri A, Calderon B, Esparza TJ et al.: Immunological reversal of autoimmune diabetes without hematopoietic replacement of β cells. Science 311(5768), 1778-1780 (2006).
175. De Coppi P, Bartsch G Jr, Siddiqui MM et al.: Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25(1), 100-106 (2007).
176. In 't Anker PS, Schedon SA, Kleijburg-van der Keur C et al.: Isolation of mesenchymal stem cells of fetal or maternal origin from
177. Yen BL, Huang HI, Chien CC et al.: Isolation of multipotent cells from human term placenta. Stem Cells 23(1), 3-9 (2005).
178. + germline progenitors. Nature 449(7160), 346-350 (2007).
179. Guan K, Nayernia K, Maier LS et al.: Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440(7088), 1199-1203 (2006).
180. Chang CM, Kao, CL, Chang YL et al.: Placenta-derived multipotent stem cells induced to differentiate into insulin-positive cells. Biochem. Biophys. Res. Commun. 357(2), 414-420 (2007).
181. Chien CC, Yen BL, Lee FK et al.: In vitro differentiation of human placenta- derived multipotent cells into hepatocyte- like cells. Stem Cells 24(7), 1759-1768 (2006).
182. Soria B, Roche E, Berria G et al.: Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin- induced diabetic mice. Diabetes 49(2), 157-162 (2000).
183. Lumelsky N, Blondel O, Laeng P et al.: Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292(5520), 1389-1394 (2001).
184. Blyszczuk P, Wobus AM: In vitro differentiation of embryonic stem cells into the pancreatic lineage. Methods Mol. Biol. 330, 373-385 (2006).
185. Hori Y, Rulifson IC, Tsai BC et al.: Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. Proc. Natl Acad. Sci. USA 99(25), 16105-16110 (2002).
186. Leon-Quinto T, Jones J, Skoudy A, Burcin M, Soria B: In vitro directed differentiation of mouse embryonic stem cells into insulin-producing cells. Diabetolegia 47(8), 1442-1451 (2004).
187. Miyazaki S, Yamato E, Miyazaki J: Regulated expression of pdx-1 promotes in vitro differentiation of insulin-producing cells from embryonic stem cells. Diabetes 53(4), 1030-1037 (2004).
188. Moritoh Y, Yamato E, Yasui Y, Miyazaki S, Miyazaki J: Analysis of insulin-producing cells during in vitro differentiation from feeder-free embryonic stem cells. Diabetes 52(5), 1163-1168 (2003).
189. Lester LB, Kuo HC, Andrews L, Nauert B, Wolf DP: Directed differentiation of rhesus monkey ES cells into pancreatic cell phenotypes. Reprod. Biol. Endocrinol. 2, 42 (2004).
190. Segev H, Fishman B, Ziskind A, Shulman M, Itskovitz-Eldor J: Differentiation of human embryonic stem cells into insulin-producing clusters. Stem Cells 22(3), 265-274 (2004).
191. Baharvand H, Jalary H, Massumi M, Ashtiani SK: Generation of insulin-secreting cells from human embryonic stem cells. Dev. Growth Differ. 48(5), 323-332 (2006).
192. D'Amour KA, Bang AG, Eliazer S et al.: Production of pancreatic hormone- expressing endocrine cells from human embryonic stem cells. Nat. Biotechnol. 24(11), 1392-1401 (2006).
193. Jiang W, Shi Y, Zhao D et al.: In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Res. 17(4), 333-344 (2007).
194. Shim JH, Kim SE, Woo DH et al.: Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. Diabetologia 50(6), 1228-1238 (2007).
195. Jiang J, Au M, Lu K et al.: Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells 25(8), 1940-1953 (2007).
196. Rajagopal J, Anderson WJ, Kume S, Martinez OI, Melton DA: Insulin staining of ES cell progeny from insulin uptake. Science 299(5605), 363 (2003).
197. Hansson M, Tonning A, Frandsen U et al.: Artifactual insulin release from differentiated embryonic stem cells. Diabetes 53(10), 2603-2609 (2004).
198. Milne HM, Burns CJ, Kitsou-Mylona I et al.: Generation of insulin-expressing cells from mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 328(2), 399-403 (2005).
199. Fujikawa T, Oh SH, Pi L et al.: Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin- producing cells. Am. J. Pathol. 166(6), 1781-1791 (2005).
200. D'Amour KA, Agulnick AD, Eliazer S et al.: Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat. Biotechnol. 23(12), 1534-1541 (2005).
201. Hammerman MR: Growing new kidneys in situ. Clin. Exp. Neophrol. 8(3), 169-177 (2004).
202. Woolf AS, Palmer SJ, Snow ML, Fine LG: Creation or a functioning chimeric mammalian kidney. Kidney Int. 38(5), 991-997 (1990).
203. Marshall D, Dilworth MR, Clancy M, Bravery CA, Ashton N: Increasing renal mass improves survival in anephric rats following metanephros transplantation. Exp. Physiol. 92(1), 263-271 (2007).
204. Rogers SA, Lowell JA, Hammerman NA, Hammerman MR: Transplantation of developing metanephroi into adult rats. Kidney Int. 54(1), 27-37 (1998).
205. Dekel B, Burakova T, Arditti FD et al.: Human and porcine early kidney precursors as a new source for transplantation. Nat. Med. 9(1), 53-60 (2003).
206. Dekel B, Reisner Y. Embryonic committed stem cells as a solution to kidney donor shortage. Expert Opin. Biol. Ther. 4(4), 443-454 (2004).
207. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q: The renal papilla is a niche for adult kidney stem cells. J. Clin. Invest. 114(6), 795-804 (2004).
208. Maeshima A, Sakurai H, Nigam SK: Adult kidney tubular cell population showing phenotypic plasticity, tubulogenic capacity, and integration capability into developing kidney. J. Am. Soc. Nephrol. 17(1), 188-198 (2006).
209. Sagrinati C, Netti GS, Mazzinghi B et al.: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J. Am. Soc. Nephrol. 17(9), 2443-2456 (2006).
210. Bussolati B, Bruno S, Grange C et al.: Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166(2), 545-555 (2005).
211. Imasawa T, Utsunomiya Y, Kawamura T et al.: The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J. Am. Soc. Nephrol. 12(7), 1401-1409 (2001).
212. Kale S, Karihaloo A, Clark PR et al.: Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J. Clin. Invest. 112(1), 42-49 (2003).
213. Lin F, Cordes K, Li L et al.: Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J. Am. Soc. Nephrol. 14(5), 1188-1199 (2003).
214. Gupta S, Verfaillie C, Chmielewski D, Kim Y, Rosenberg ME: A role for extrarenal cells in the regeneration following acute renal failure. Kidney Int. 62(4), 1285-1290 (2002).
215. Rookmaaker MB, Smits AM, Tolboom H et al.: Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am. J. Pathol. 163(2), 553-562 (2003).
216. Rookmaaker MB, Tolboom H, Goldschmeding R et al.: Bone-marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy. Blood 99(3), 1095 (2002).
217. Duffield JS, Bonventre JV: Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int. 68(5), 1956-1961 (2005).
218. Lin F, Moran A, Igarashi P: Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J. Clin. Invest. 115(7), 1756-1764 (2005).
219. Kunter U, Rong S, Djuric Z et al.: Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J. Am. Soc. Nephrol. 17(8), 2202-2212 (2006).
220. Sugimoto H, Mundel TM, Sund M et al.: Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl Acad. Sci. USA 103(19), 7321-7326 (2006).
221. Li B, Morioka T, Uchiyama M, Oite T: Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model. Kidney Int. 69(2), 323-330 (2006).
222. Krause D, Cantley LG: Bone marrow plasticity revisited: protection or differentiation in the kidney tubule? J. Clin. Invest. 115(7), 1705-1708 (2005).
223. Asahara T, Murohara T, Sullivan A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997).
224. Cho HJ, Kim HS, Lee MM et al.: Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation 108(23), 2918-2925 (2003).
225. Capla JM, Grogan RH, Callaghan MJ et al.: Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plast. Reconstr. Surg. 119(1), 59-70 (2007).
226. Fadini GP, Miorin M, Facco M et al.: Circulating endothelial progenitor cells are reduced in peripheral vascular complications of Type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45(9), 1449-1457 (2005).
227. Thum T, Fraccarollo D, Schultheiss M et al.: Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56(3), 666-674 (2007).
228. Zhou B, Cao XC, Fang ZH et al.: Prevention of diabetic microangiopathy by prophylactic transplant of mobilized peripheral blood mononuclear cells. Acta Pharmacol. Sin. 28(1), 89-97 (2007).
229. Fadini GP, Sartore S, Schiavon M et al.: Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 49(12), 3075-3084 (2006).
230. Fadini GP, Sartore S, Albiero M et al.: Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler. Thromb. Vasc. Biol. 26(9), 2140-2146 (2006).
231. Lee IG, Chae SL, Kim JC: Involvement of circulating endothelial progenitor cells and vasculogenic, factors in the pathogenesis of diabetic retinopathy. Eye 20(5), 546-552 (2006).
232. Goon PK, Lip GY: Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye 21(6), 838-839; author reply 838 (2007).
233. Kusuyama T, Omura T, Nishiya D et al.: Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J. Pharmacol. Sci. 102(1), 96-102 (2006).
234. Asnaghi V, Lattanzio R, Mazzolari G et al.: Increased clonogenic potential of circulating endothelial progenitor cells in patients with Type 1 diabetes and proliferative retinopathy. Diabetologia 49(5), 1109-1111 (2006).
235. Fadini GP, Sartore S, Baesso I et al.: Endothelial progenitor cells and the diabetic paradox. Diabetes Care 29(3), 714-716 (2006).
236. Naruse K, Hamada Y, Nakashima E et al.: Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 54(6), 1823-1828 (2005).
237. Malik RA, Veves A, Tesfaye S: Ameliorating human diabetic neuropathy: lessons from implanting hematopoietic mononuclear cells. Exp. Neurol. 201(1), 7-14 (2006).
238. Hasegawa T, Kosaki A, Shimizu K et al.: Amelioration of diabetic peripheral neuropathy by implantation of hematopoietic mononuclear cells in streptozotocin-induced diabetic rats. Exp. Neurol. 199(2), 274-280 (2006).
239. Kajiguchi M, Kondo T, Izawa H et al.: Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ. J. 71(2), 196-201 (2007).
240. Kawamura A, Horie T, Tsuda I et al.: Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically Ischemic limbs. J. Artif. Organs 9(4), 226-233 (2006).
241. Rota M, LeCapitaine N, Hosoda T et al.: Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ. Res. 99(1), 42-52 (2006).
242. Vojtassak J, Danisovic L, Kubes M et al.: Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro. Endocrinol. Lett. 27(Suppl. 2), 134-137 (2006).
243. Xia Z, Ye H, Choong C et al.: Macrophagic response to human mesenchymal stem cell and poly(ε-caprolactone) implantation in nonobese diabetic/severe combined immunodeficient mice. J. Biomed. Mater. Res. A. 71(3), 538-548 (2004).
244. Kirana S, Stratmann B, Lammers D et al.: Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs. Int. J. Clin. Pract. 61(4), 690-692 (2007).
245. Urban VS, Kiss J, Kovacs J et al.: Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 26(1), 244-253 (2008).
246. Burt RK, Traynor A, Statkute L et al.: Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295(5), 527-535 (2006).